文献速递消化系统肿瘤

呋喹替尼治疗转移性结直肠癌患者的健康相关生活质量:FRESCO-2研究结果

Health-related quality of life associated with fruquintinib in patients with metastatic colorectal cancer: Results from the FRESCO-2 study.
PubMed 文献 · Eur J Cancer · 2025-01-29

FRESCO-2研究纳入转移性结直肠癌患者,随机接受呋喹替尼+最佳支持治疗(n=461)或安慰剂+最佳支持治疗(n=230)。呋喹替尼组与安慰剂组相比,QLQ-C30总体健康状况和EQ-5D视觉模拟量表评分从基线的变化在治疗期间波动,至恶化时间延迟,且ECOG体能状态至恶化时间延长,未对健康相关生活质量产生负面影响。

要点

  • 呋喹替尼组QLQ-C30总体健康状况至恶化中位时间2.1个月 vs 安慰剂组1.8个月(HR 0.9,95%CI 0.7-1.0)。
  • 呋喹替尼组EQ-5D视觉模拟量表至恶化中位时间2.6个月 vs 安慰剂组1.9个月(HR 0.8,95%CI 0.6-0.9)。
  • 呋喹替尼组ECOG体能状态≥2或末次治疗后30+7天内死亡至恶化中位时间6.6个月 vs 安慰剂组2.9个月(HR 0.6,95%CI 0.4-0.7)。

核心结论

  • 呋喹替尼延迟了ECOG体能状态至恶化时间,且与安慰剂相比未对健康相关生活质量产生负面影响。

研究设计与样本

  • FRESCO-2研究(NCT04322539)为随机研究,患者随机接受呋喹替尼+最佳支持治疗(n=461)或安慰剂+最佳支持治疗(n=230),使用EORTC QLQ-C30、5级EQ-5D和ECOG体能状态进行评估。

主要发现

  • 基线时,呋喹替尼组与安慰剂组的QLQ-C30总体健康状况评分分别为65.2 vs 64.6,EQ-5D视觉模拟量表评分分别为67.0 vs 66.6。
  • 治疗结束时,呋喹替尼组与安慰剂组的QLQ-C30总体健康状况平均评分分别为53.8 vs 52.3,EQ-5D视觉模拟量表平均评分分别为58.9 vs 58.5。
  • 治疗结束时,呋喹替尼组与安慰剂组分别有38.3% vs 36.5%的患者QLQ-C30总体健康状况评分稳定或改善;中位至恶化时间分别为2.1 vs 1.8个月(HR 0.9,95%CI 0.7-1.0)。
  • 治疗结束时,呋喹替尼组与安慰剂组分别有47.9% vs 42.7%的患者EQ-5D视觉模拟量表评分稳定或改善;中位至恶化时间分别为2.6 vs 1.9个月(HR 0.8,95%CI 0.6-0.9)。
  • 呋喹替尼组与安慰剂组ECOG体能状态≥2或末次治疗后30+7天内死亡的中位至恶化时间分别为6.6 vs 2.9个月(HR 0.6,95%CI 0.4-0.7)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Maintaining or improving health-related quality of life (HRQoL) is as important as extending survival in metastatic colorectal cancer. We report an HRQoL analysis from FRESCO-2 (NCT04322539). METHODS: Patients were randomized to fruquintinib +best supportive care (BSC; n = 461) or placebo +BSC (n = 230). Instruments of EORTC QLQ-C30 and 5-level EQ-5D, and ECOG performance status (PS) were assessed. Changes from baseline scores for QLQ-C30 and EQ-5D were evaluated and minimally important difference thresholds were used to define stable, improved, or deteriorated QoL. Time to deterioration (TTD) was assessed. RESULTS: With fruquintinib versus placebo, baseline QLQ-C30 global health status (GHS) and EQ-5D visual analog scale (VAS) scores were 65.2 versus 64.6 and 67.0 versus 66.6, respectively. Least-squares mean changes from baseline fluctuated throughout treatment. At end of treatment (EOT), mean scores with fruquintinib versus placebo were 53.8 versus 52.3 (QLQ-C30 GHS) and 58.9 versus 58.5 (EQ-5D VAS). For QLQ-C30 GHS, 38.3 % versus 36.5 % of patients receiving fruquintinib versus placebo had stable or improved scores at EOT; median TTD was 2.1 versus 1.8 months (HR, 0.9; 95 % CI, 0.7-1.0). For EQ-5D VAS, 47.9 % versus 42.7 % had stable or improved scores at EOT; median TTD was 2.6 versus 1.9 months (HR, 0.8; 95 % CI, 0.6-0.9). Median TTD to ECOG PS ≥ 2 or death within 30+ /7 days after EOT was 6.6 versus 2.9 months with fruquintinib versus placebo (HR, 0.6; 95 % CI, 0.4-0.7). CONCLUSIONS: Fruquintinib delayed TTD of ECOG PS and did not negatively impact HRQoL versus placebo.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Sobrero A, Dasari A, Aquino J, et al. Health-related quality of life associated with fruquintinib in patients with metastatic colorectal cancer: Results from the FRESCO-2 study. Eur J Cancer. 2025. PMID: 39952149. doi:10.1016/j.ejca.2025.115268

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。